Physician profile
Stanley Skopit
NPI 1902865587
$12,039.32
in general payments reported to CMS, 2019-2025
34 companies · $2,120 in 2025
The $2,120 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,059 · 2020: $1,080 · 2021: $1,410 · 2022: $1,631 · 2023: $2,003 · 2024: $1,737 · 2025: $2,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,859.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,676.18 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Genzyme Corporation | $1,343.52 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,157.41 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $1,090.81 | 2019-2025 | |
| Amgen INC. | $604.82 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $496.58 | 2019-2025 | |
| Janssen Biotech, INC. | $472.48 | 2019-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $422.51 | 2023-2025 | Zoryve |
| Botanix Sb INC | $390.32 | 2025 | Sofdra |
| Lilly USA, LLC | $389.11 | 2019-2025 | Taltz, Ebglyss |
| Genentech USA, INC. | $369.59 | 2019-2021 | |
| Ucb, INC. | $348.08 | 2020-2025 | Cimzia, Bimzelx |
| Galderma Laboratories, L.P. | $261.01 | 2022-2025 | Nemluvio, Aklief, Epsolay |
| Janssen Scientific Affairs, LLC | $236.88 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $218.28 | 2022-2024 | Sotyktu |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $185.73 | 2020-2025 | Odomzo, Blu-U |
| Dermavant Sciences, INC. | $172.77 | 2023-2024 | Vtama |
| Strata Skin Sciences, INC. | $161.14 | 2021-2025 | Xtrac |
| Allergan, INC. | $155.40 | 2021-2022 | |
| Incyte Corporation | $138.13 | 2021-2025 | Opzelura |
| Smith+Nephew, INC. | $132.64 | 2021-2023 | Collagenase Santyl |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $124.73 | 2019-2025 | Cabtreo, Jublia, Arazlo |
| Leo Pharma INC. | $112.46 | 2021-2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $87.87 | 2021 | |
| Celgene Corporation | $71.44 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $54.82 | 2022-2023 | Valchlor |
| Biofrontera INC. | $30.55 | 2022-2024 | Rhodoled Xl, Ameluz, Xepi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.20 | 2024 | Spevigo |
| Kerecis Limited | $21.67 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Vyne Pharmaceuticals INC. | $21.50 | 2020 | |
| Epi Health, LLC | $19.48 | 2022 | |
| Misonix INC | $16.49 | 2021 | |
| Almirall LLC | $14.91 | 2021 | |
| Paratek Pharmaceuticals, INC. | $12.81 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Skopit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.